27 related articles for article (PubMed ID: 38518533)
21. Adjuvant therapy for resected stage III melanoma patients: high-dose interferon-alpha versus ipilimumab combined with kinases inhibitors.
Minutilli E; Feliciani C
Tumori; 2012; 98(2):185-90. PubMed ID: 22677983
[TBL] [Abstract][Full Text] [Related]
22. Neo-Adjuvant Therapy for Metastatic Melanoma.
Kuijpers AMJ; van Akkooi ACJ
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38610925
[TBL] [Abstract][Full Text] [Related]
23. Outcome of adjuvant immunotherapy in a real-world nation-wide cohort of patients with melanoma.
Holmstroem RB; Pedersen S; Jurlander R; Madsen K; Donia M; Ruhlmann CH; Schmidt H; Haslund CA; Bastholt L; Svane IM; Ellebaek E
Eur J Cancer; 2024 May; 202():114023. PubMed ID: 38518533
[TBL] [Abstract][Full Text] [Related]
24. Novel adjuvant options for cutaneous melanoma.
Dimitriou F; Long GV; Menzies AM
Ann Oncol; 2021 Jul; 32(7):854-865. PubMed ID: 33771664
[TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant treatment for stage III and IV cutaneous melanoma.
Gorry C; McCullagh L; O'Donnell H; Barrett S; Schmitz S; Barry M; Curtin K; Beausang E; Barry R; Coyne I
Cochrane Database Syst Rev; 2023 Jan; 1(1):CD012974. PubMed ID: 36648215
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials.
Hao C; Tian J; Liu H; Li F; Niu H; Zhu B
Medicine (Baltimore); 2017 Jun; 96(26):e7325. PubMed ID: 28658143
[TBL] [Abstract][Full Text] [Related]
27. Treatment of High Risk Resected Melanoma in Australia: Current Landscape and Practises.
Bhave P; Haydon A
Australas J Dermatol; 2020 Aug; 61(3):203-209. PubMed ID: 32403192
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]
